Tapimmune Inc (TPIVD) 4.6000 $TPIVD
TapImmune Inc. to Present at Invitation Only Corporate Roadshow in Boca Raton Florida
ACCESSWIRE - Thu Apr 24, 8:11AM CDT
Seattle WA / ACCESSWIRE / April 24, 2014 / TapImmune Inc. (OTCQB: TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to announce that the company will be presenting at Corporate Road Show.com, in conjunction with, Undiscovered Equities.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
TapImmune Inc. is Pleased to Provide an Update on Corporate Events and Milestones for 2014
Business Wire - Thu Apr 03, 10:03AM CDT
TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead. Glynn Wilson TapImmune's CEO provided insights in an interview on the floor of the NASDAQ recently which can be seen by navigating to the following link:
TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart(TM)
Business Wire - Thu Mar 20, 7:47AM CDT
TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient's immune system, a critical aspect of an effective vaccine.
TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer
Business Wire - Wed Mar 19, 7:45AM CDT
TapImmune Inc. (OTCQB: TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference
ACCESSWIRE - Wed Mar 05, 7:31AM CST
Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
Business Wire - Mon Mar 03, 7:00AM CST
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
Business Wire - Thu Feb 27, 8:38AM CST
TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
TapImmune Inc. to Present at Invitation Only Corporate Roadshow in Boca Raton Florida
ACCESSWIRE - Thu Apr 24, 8:11AM CDT
Seattle WA / ACCESSWIRE / April 24, 2014 / TapImmune Inc. (OTCQB: TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to announce that the company will be presenting at Corporate Road Show.com, in conjunction with, Undiscovered Equities.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
TapImmune Inc. is Pleased to Provide an Update on Corporate Events and Milestones for 2014
Business Wire - Thu Apr 03, 10:03AM CDT
TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead. Glynn Wilson TapImmune's CEO provided insights in an interview on the floor of the NASDAQ recently which can be seen by navigating to the following link:
TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart(TM)
Business Wire - Thu Mar 20, 7:47AM CDT
TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient's immune system, a critical aspect of an effective vaccine.
TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer
Business Wire - Wed Mar 19, 7:45AM CDT
TapImmune Inc. (OTCQB: TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference
ACCESSWIRE - Wed Mar 05, 7:31AM CST
Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
Business Wire - Mon Mar 03, 7:00AM CST
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
Business Wire - Thu Feb 27, 8:38AM CST
TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
